This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameMitoguazone
Accession NumberDB12967
TypeSmall Molecule
GroupsInvestigational
Description

Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIOD5Q0L447W
CAS number459-86-9
WeightAverage: 184.207
Monoisotopic: 184.118492418
Chemical FormulaC5H12N8
InChI KeyMXWHMTNPTTVWDM-VEPASKNESA-N
InChI
InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3?
IUPAC Name
N-{[(1E)-1-(carbamimidamidoimino)propan-2-ylidene]amino}guanidine
SMILES
CC(\C=N\NC(N)=N)=NNC(N)=N
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mitoguazone.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Mitoguazone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitoguazone.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mitoguazone.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mitoguazone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mitoguazone.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Mitoguazone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoguazone.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Mitoguazone.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Mitoguazone.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoguazone.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mitoguazone.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL01XX16 — Mitoguazone
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3TerminatedTreatmentMalignant Lymphomas1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.313 mg/mLALOGPS
logP0.24ALOGPS
logP-1.2ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)17.98ChemAxon
pKa (Strongest Basic)9.06ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area148.52 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity90.67 m3·mol-1ChemAxon
Polarizability18.47 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as guanidines. These are compounds containing a guanidine moiety, with the general structure (R1R2N)(R3R4N)C=N-R5.
KingdomOrganic compounds
Super ClassOrganic nitrogen compounds
ClassOrganonitrogen compounds
Sub ClassGuanidines
Direct ParentGuanidines
Alternative ParentsHydrocarbon derivatives
SubstituentsGuanidine / Hydrocarbon derivative / Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 19:38 / Updated on September 01, 2017 12:26